DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Clinical trial NCT06027086 · RECRUITING
Trial details
- NCT number
- NCT06027086
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-12
- Primary completion
- 2028-09-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.